ProCE Banner Activity

KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM

Slideset Download
Conference Coverage
Early-phase study of pembrolizumab plus lenalidomide plus dexamethasone in heavily pretreated MM showed 50% ORR, including a 38% rate in lenalidomide-refractory patients.

Released: June 08, 2016

Expiration: June 07, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals